A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 1,006
- 试验地点
- 171
- 主要终点
- Number of participants with dose-limiting toxicities (DLTs)
研究概览
简要总结
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether sigvotatug vedotin works to treat solid tumors.
The study will have four parts.
-
Part A of the study will find out how much sigvotatug vedotin should be given to participants.
-
Part B will use the dose found in Part A to find out how safe sigvotatug vedotin is and if it works to treat solid tumors.
-
Part C of the study will find out how safe sigvotatug vedotin is in combination with these other drugs.
-
Part D will include people who have not received treatment. This part of the study will find out how safe sigvotatug vedotin is in combination with these other drugs and if these combinations work to treat solid tumors.
-
In Parts C and D, participants will receive sigvotatug vedotin with either:
-
Pembrolizumab or,
-
Pembrolizumab and carboplatin, or
-
Pembrolizumab and cisplatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease indication
- •Participants must have histologically or cytologically confirmed metastatic or unresectable solid malignancy within one of the tumor types listed below (dependent on study part).
- •Non-small cell lung cancer (NSCLC)
- •Head and neck squamous cell cancer (HNSCC)
- •Advanced HER2-negative breast cancer
- •Esophageal squamous cell carcinoma (ESCC)
- •Esophageal/Gastro-esophageal junction adenocarcinoma (EAC/GEJ)
- •Cutaneous squamous cell cancer (cSCC)
- •Exocrine pancreatic adenocarcinoma
- •Bladder cancer
- •Cervical cancer
- •Gastric cancer
- •High grade serous ovarian cancer (HGSOC)
- •Part A only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies and should have no appropriate standard-of-care therapeutic options.
- •Part B only: Participants must have disease that is relapsed or refractory or be intolerant to standard-of-care therapies. Participants must have received platinum-based therapy and a PD-1/PD-(L)1 inhibitor, if applicable and available.
- •Part C only: For pembrolizumab combination cohorts, participants must be eligible for pembrolizumab per local standard of care. For pembrolizumab with cisplatin or carboplatin, participants must be eligible for both pembrolizumab and the platinum agent per local standard of care. Participants must be treatment naïve for locally advanced or metastatic systemic therapy (prior definitively intended or [neo]adjuvant therapy is allowed).
- •Part D only: Participants must be treatment naïve for locally advanced or metastatic systemic therapy.
- •Participants enrolled in the following study parts should have a tumor site accessible for biopsy and agree to biopsy as follows:
- •Disease-specific expansion cohorts (Part B and Part D): A baseline fresh tumor biopsy is required. An archival biopsy collected within 90 days prior to first dose of study drug may be used.
- •Biology expansion cohort: pretreatment biopsy and on-treatment (Cycle 1) biopsy
- •An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Measurable disease per the RECIST v1.1 at baseline
排除标准
- •History of another malignancy within 3 years before first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
- •Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:
- •are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment,
- •have no new or enlarging brain metastases, and
- •are off of corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to first dose of study drug.
- •In Part D, participants with untreated, asymptomatic CNS metastases smaller than 1 cm may be enrolled without definitive treatment as long as they have no neurological symptoms, no or minimal surrounding edema, and no requirements for corticosteroids.
- •Carcinomatous meningitis
- •Previous receipt of an MMAE-containing agent or an agent targeting integrin beta-6
- •Pre-existing neuropathy Grade 1 or greater per the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) for Parts C and D cohorts with cisplatin or carboplatin; Grade 2 or greater per the NCI CTCAE v5.0 for all other cohorts
- •Any uncontrolled Grade 3 or higher (per NCI CTCAE v5.0) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of sigvotatug vedotin.
- •Routine antimicrobial prophylaxis is permitted
- •Grade ≥3 pulmonary disease unrelated to underlying malignancy. This includes clinically severe pulmonary function compromise resulting from clinically significant pulmonary illnesses
- •Part C and D: Prior therapy with a PD-1 inhibitor, anti-PD-(L)1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor and was discontinued from that treatment due to a Grade 3 or higher immune-mediated adverse event (IMAE).
- •History of noninfectious interstitial lung disease (ILD) or pneumonitis that required steroids, current ILD or pneumonitis, or suspected ILD or pneumonitis that cannot be ruled out by imaging at screening
- •Known diffusing capacity of the lung for carbon monoxide (DLCO; adjusted for hemoglobin) <50% predicted
- •Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
研究组 & 干预措施
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: cisplatin (Drug)
Part D: sigvotatug vedotin combination therapy in 1L NSCLC
sigvotatug vedotin + pembrolizumab +/- (carboplatin)
干预措施: sigvotatug vedotin (Drug)
Part D: sigvotatug vedotin combination therapy in 1L NSCLC
sigvotatug vedotin + pembrolizumab +/- (carboplatin)
干预措施: pembrolizumab (Drug)
Part D: sigvotatug vedotin combination therapy in 1L HNSCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: pembrolizumab (Drug)
Part D: sigvotatug vedotin combination therapy in 1L HNSCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: carboplatin (Drug)
Part D: sigvotatug vedotin combination therapy in 1L HNSCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: sigvotatug vedotin (Drug)
Part D: sigvotatug vedotin combination therapy in 1L HNSCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: cisplatin (Drug)
Part D: sigvotatug vedotin combination therapy in 1L NSCLC
sigvotatug vedotin + pembrolizumab +/- (carboplatin)
干预措施: carboplatin (Drug)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: carboplatin (Drug)
Part A: Dose escalation
sigvotatug vedotin monotherapy
干预措施: sigvotatug vedotin (Drug)
Part B: Dose expansion
sigvotatug vedotin monotherapy
干预措施: sigvotatug vedotin (Drug)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: sigvotatug vedotin (Drug)
Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC
sigvotatug vedotin + pembrolizumab +/- (carboplatin or cisplatin)
干预措施: pembrolizumab (Drug)
结局指标
主要结局
Number of participants with dose-limiting toxicities (DLTs)
时间窗: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
Number of participants with adverse events (AEs)
时间窗: Through 30-37 days following last dose of sigvotatug vedotin. For participants receiving pembrolizumab up to 90 days after last dose of pembrolizumab; up to 3 years
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment.
Number of patients with laboratory abnormalities
时间窗: Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years
次要结局
- Overall survival (OS)(Up to approximately 3 years)
- Maximum observed concentration (Cmax)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Trough concentration (Ctrough)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Number of participants with antidrug antibodies (ADAs)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Area under the concentration-time curve (AUC)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Concentration at the end of infusion (Ceoi)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Time to maximum observed concentration (Tmax)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)
- Duration of objective response (DOR) per RECIST v1.1 by investigator assessment(Up to approximately 3 years)
- Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by investigator assessment(Up to approximately 3 years)
- Progression-free survival (PFS) per RECIST v1.1 by investigator assessment(Up to approximately 3 years)
- Apparent terminal elimination half-life (t1/2)(Through 30-37 days following last dose of sigvotatug vedotin; up to 3 years)